This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, T.-Y. Articles by Lin, C.-T. Search for Related Content PubMed PubMed Citation Articles by Lee, T.-Y. Articles by Lin, C.-T.

A Novel Peptide Specifically Binding to Nasopharyngeal Carcinoma For Targeted Drug Delivery

¹ Institute of Pathology and ² Graduate Institute of Oral Biology, College of Medicine, National Taiwan University; and ³ Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan

Nasopharyngeal carcinoma (NPC) is a common cancer among Chinese living in southern China, Taiwan, and Singapore. The 5-year survival rate in the early stage of NPC has been reported as high as 90 to 95% with the use of radiotherapy, but in the advanced cases, even with the use of both chemotherapy and radiotherapy, the survival rate is still <50%. To improve the survival rate, we identify a 12-mer peptide (L-peptide) specifically binding to NPC cells with a phage displayed random peptide library. The L-phage and synthetic L-peptide bound to the tumor cell surfaces of most NPC cell lines and biopsy specimens, but not normal nasal mucosal cells, and the L-peptide–linked liposomes containing fluorescent substance (L-peptide-Lipo-HPTS) were capable of binding to and translocating across plasma membranes. L-Peptide–linked liposomes that carried doxorubicin (L-peptide-Lipo-Dox) caused marked cytotoxicity in NPC cells. In SCID mice bearing NPC xenografts, the L-phages specifically bound to the tumor mass, an effect that was inhibited by competition with synthetic L-peptide. In addition, the L-peptide-Lipo-Dox suppressed tumor growth better than Lipo-Dox. These results indicate that the novel L-peptide specifically binds NPC cells and is a good candidate for targeted drug delivery to NPC solid tumors.

This article has been cited by other articles:

				A. Lo, C.-T. Lin, and H.-C. Wu Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery Mol. Cancer Ther., March 1, 2008; 7(3): 579 - 589. [Abstract] [Full Text] [PDF]

				T.-Y. Lee, C.-T. Lin, S.-Y. Kuo, D.-K. Chang, and H.-C. Wu Peptide-Mediated Targeting to Tumor Blood Vessels of Lung Cancer for Drug Delivery Cancer Res., November 15, 2007; 67(22): 10958 - 10965. [Abstract] [Full Text] [PDF]

				Y.-C. Chen, H.-N. Huang, C.-T. Lin, Y.-F. Chen, C.-C. King, and H.-C. Wu Generation and Characterization of Monoclonal Antibodies against Dengue Virus Type 1 for Epitope Mapping and Serological Detection by Epitope-Based Peptide Antigens Clin. Vaccine Immunol., April 1, 2007; 14(4): 404 - 411. [Abstract] [Full Text] [PDF]

				S.-M. Lee, E.-J. Lee, H.-Y. Hong, M.-K. Kwon, T.-H. Kwon, J.-Y. Choi, R.-W. Park, T.-G. Kwon, E.-S. Yoo, G.-S. Yoon, et al. Targeting Bladder Tumor Cells In vivo and in the Urine with a Peptide Identified by Phage Display Mol. Cancer Res., January 1, 2007; 5(1): 11 - 19. [Abstract] [Full Text] [PDF]